Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ondansetron: pre-clinical safety evaluation.

M L Tucker1, M R Jackson, M D Scales

  • 1Pathology and Toxicology Division, Glaxo Group Research Limited, Ware, Hertsfordshire, U.K.

European Journal of Cancer & Clinical Oncology
|January 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Re: Imaging inequality: exploring the differences in radiology between high- and low-income countries.

Clinical radiology·2024
Same author

Sustainable imaging in the era of the climate emergency: a personal view.

Clinical radiology·2023
Same author

Re: A bump in the night: a 15-year retrospective analysis of urgent inpatient and emergency CT reporting out of hours in a tertiary referral centre.

Clinical radiology·2022
Same author

Re: CT coronary angiography-guided cardiovascular risk screening in asymptomatic patients: is it time?

Clinical radiology·2021
Same author

Serum anti-GM2 and anti-GalNAc-GD1a IgG antibodies are biomarkers for acute canine polyradiculoneuritis.

The Journal of small animal practice·2021
Same author

Molecular characterization of a tomato polygalacturonase gene abundantly expressed in the upper third of pistils from opened and unopened flowers.

Plant cell reports·2019

Pre-clinical safety evaluations demonstrate ondansetron has an excellent safety profile. The only identified toxicity was central nervous system effects at near lethal doses, with no genotoxic, reproductive, or oncogenic potential.

Area of Science:

  • Pharmacology and Toxicology
  • Drug Safety Assessment

Background:

  • Ondansetron is a widely used antiemetic medication.
  • Comprehensive pre-clinical safety data is crucial for drug approval and clinical use.

Purpose of the Study:

  • To conduct a thorough pre-clinical safety evaluation of ondansetron.
  • To identify any potential toxicities, genotoxic, reproductive, or oncogenic effects.

Main Methods:

  • A series of pre-clinical safety studies were performed.
  • These included single and repeat dose toxicity, reproduction, genotoxicity, oncogenicity, local irritancy, and hypersensitivity studies.

Main Results:

  • Ondansetron exhibited a very good overall safety profile.
  • The primary toxicity observed was central nervous system effects at near lethal doses.

Related Experiment Videos

  • No genotoxic, reproductive, or oncogenic potential was detected.

    • Conclusions:

    • Ondansetron demonstrates a favorable pre-clinical safety profile.
    • The drug is considered safe for further clinical development based on these findings.